33 results about "ERBB2 Antibody" patented technology

The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.

This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and / or C1 antibodies attached to one or more effector molecules are also provided.

An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.

The present invention relates to an antibody that specifically binds to ErbB2. The antibody can bind to ErbB2 protein with higher affinity, and has the ability to inhibit the proliferation of SK-BR3 breast cancer cells with high ErbB2 expression and at the same time inhibit the low expression of ErbB2 induced by Heregulin β MCF‑7 breast cancer cell proliferation and other biological activities.

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.

The invention discloses an ErbB2 antigen epitope peptide bonded with an E9 antibody. The ErbB2 antigen epitope peptide disclosed by the invention is an antigen epitope peptide respectively named as A1and / or B1, wherein A1 contains amino acid residues as follows: Arg at a site 136 of a sequence 6 in a sequence table, Pro at a site 138, Cys at a site 141, Tyr at a site 142 and Asp at a site 144; and B2 contains amino acid residues as follows: Asn at a site 141 of the sequence 6 in the sequence table, Arg at a site 167, Cys at a site 171, His at a site 172 and Glu at a site 186. Compared with abonding region between chA21 and ErbB2, an ErbB2 antibody, antigen epitope peptide bonded with the ErbB2 antibody and antigen epitope have the advantages that the bonding sequences between E9 and ErbB2 are reduced, and the preparation of new ErbB2 antibody is promoted.

The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with a low amount.

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.

The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.

The invention belongs to a biomedical technology field. The invention provides an anti-human ErbB2 antibody and ansamitocin conjugate, comprising: substituting lysine at 30 or / and 65 position in a heavy chain variable region of Trastuzumab with a hydrophilic amino acid, and then coupling with ansamitocin (DM1). On basis of maintaining coupling Pharmaceutical activity, a proportion of ansamitocin in a coupling medicament is reduced, thereby reducing toxic and side effect of the coupling medicament. The invention further provides applications of the anti-human ErbB2 antibody and ansamitocin conjugate for preparing antitumor drugs.

The present invention relates to the combined application of ErbB2 antibody and Saracatinib in the preparation of drugs for treating breast cancer. When the ErbB2 antibody of the present invention is used in combination with Saracatinib, it can synergistically inhibit the growth of ErbB2-positive tumors and has broad application prospects.

Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2 / HER3 and / or HER2 / HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER / 2 / HER1 and / or HER2 / HER3 heterodimers and / or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.